BUZZ-Praxis Precision climbs after FDA's 'breakthrough' tag for tremor drug** Shares of drug developer Praxis Precision Medicines PRAX.O rise 11.5% to $299.9 premarket
** PRAX says U.S. Food and Drug Administration has granted "breakthrough" tag for its experimental drug, ulixacaltamide, to treat patients with essential tremor
** The breakthrough therapy tag is meant to speed up development and review of drugs to treat a serious condition or those with unmet medical need
** Essential tremor is a neurological movement disorder that causes involuntary, rhythmic shaking in hands, arms, head or voice
** As of last close, stock has more than tripled YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments